Karyopharm Therapeutics (KPTI):Selinexor At ASH Could Drive Upside - Jefferies
Get Alerts KPTI Hot Sheet
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 7
Join SI Premium – FREE
Jefferies analyst, Brian Abrahams reiterated his Buy rating on shares of Karyopharm Therapeutics (NASDAQ: KPTI) and raised his price target to $14 thinking that a full presentation of its STORM and STOMP selinexor data -- as well as add'l data on selinexor in MM and AML, and next-gen '8602 -- could draw increasing attention to the activity and promise of its XPO1 inhibitor platform.
The analyst sees an opportunity for continued upside through and following ASH, which drives the PT up to $14 from $12.
For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.
Shares of Karyopharm Therapeutics closed at $9.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WesBanco (WSBC) PT Lowered to $35 at DA Davidson
- Capitol Federal Financial (CFFN) PT Lowered to $5.50 at Piper Sandler
- Chipotle Mexican Grill (CMG) PT Raised to $3,070 at Piper Sandler
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!